At-home Leqembi can cause injection-site reactions, headache, fatigue, fever, serious allergic reactions, and amyloid-related imaging abnormalities, or ARIA. ARIA involves brain swelling, small areas of bleeding, or both; it is often detectable only on MRI but can become life-threatening. For example, a person who develops a new severe headache, confusion, blurred vision, or trouble walking after a weekly injection needs prompt medical assessment rather than assuming the symptoms are part of Alzheimer’s disease. Home administration does not remove the need for specialist oversight.
The FDA-approved Leqembi IQLIK starting regimen is 500 milligrams once weekly, delivered as two 250-milligram injections; after 18 months, a 360-milligram weekly maintenance regimen is an option. Patients still need a baseline MRI, scheduled follow-up MRIs, genetic risk counseling, medication review, and a clear emergency plan. The new at-home initiation regimen was approved in July 2026, with its U.S. launch planned for late August 2026, while the maintenance formulation was already approved. FDA prescribing information.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What At-Home Leqembi Side Effects and ARIA Warning Signs Should Families Watch For?
- ARIA Risk, MRI Monitoring, and the First Months of Treatment
- Injection Reactions Versus Serious Allergic Reactions
- How to Monitor and Give At-Home Leqembi Safely
- Blood Thinners, APOE4, and Other Advanced Risk Issues
- Keeping an At-Home Side-Effect Record
- Missed Doses and When the Next Injection Should Wait
- Frequently Asked Questions
What At-Home Leqembi Side Effects and ARIA Warning Signs Should Families Watch For?
ARIA is divided into ARIA-E, which refers to edema or fluid-related swelling, and ARIA-H, which refers to blood products such as microhemorrhages or superficial siderosis. Most ARIA detected in Leqembi studies did not produce obvious symptoms, which is why feeling well cannot replace MRI monitoring. When symptoms occur, they can include headache, nausea, dizziness, confusion, visual changes, difficulty walking, or focal neurological problems such as weakness or speech difficulty. The difficult comparison is between ARIA and ordinary day-to-day changes.
A mild familiar headache that resolves may have many causes, but a new or worsening headache accompanied by confusion, unsteadiness, weakness, or vision changes requires urgent attention. ARIA-E can resemble an ischemic stroke, so emergency clinicians need to know that the patient receives lecanemab before considering clot-dissolving treatment. Seizures, loss of consciousness, sudden one-sided weakness, facial drooping, new speech trouble, severe confusion, abrupt vision loss, or an unusually severe headache warrant emergency care. A caregiver should bring the Leqembi medication information or show it on a phone because brain hemorrhage and severe ARIA can be fatal, even though such outcomes are uncommon.
ARIA Risk, MRI Monitoring, and the First Months of Treatment
ARIA is most likely to occur early in treatment, and the prescribing information calls for heightened vigilance during the first 14 weeks. Patients need a recent baseline brain MRI and additional MRIs after approximately one, two, three, and six months of treatment. For weekly subcutaneous treatment, the one-month scan may occur before the fifth dose; the scan should generally be completed and reviewed before the next scheduled injection. FDA Leqembi label Scheduled scans have an important limitation: ARIA can arise between appointments.
If symptoms appear, the care team may order an unscheduled MRI and pause treatment. Depending on whether ARIA-E or ARIA-H is present, its severity on imaging, and whether symptoms interfere with daily activities, the prescriber may continue dosing, temporarily suspend it, or reconsider treatment. In the pivotal intravenous study, symptomatic ARIA occurred in 3% of Leqembi-treated participants, while ARIA visible on imaging—including cases without symptoms—occurred in 21%. Those figures came primarily from intravenous treatment data; the subcutaneous formulation’s expected benefit and ARIA profile rely partly on pharmacokinetic and exposure-response comparisons rather than a separate large placebo-controlled clinical-outcomes trial of at-home initiation.
Injection Reactions Versus Serious Allergic Reactions
Subcutaneous Leqembi can cause redness, warmth, swelling, hardness, itching, pain, rash, a bump, bruising, or a collection of blood under the skin. Headache, chills, fever, and fatigue can also occur after an injection. In open-label subcutaneous studies, most injection-related reactions were localized, many arose with the first starting dose, and delayed or recurring reactions were observed several days after an injection. For example, a small tender red patch confined to the injection site differs from hives spreading across the body, swelling of the lips or tongue, or shortness of breath.
The localized reaction should be recorded and reported to the prescriber, particularly if it is severe, expands, recurs, or interferes with subsequent injections. Facial, mouth, or tongue swelling, breathing difficulty, faintness, or widespread hives may indicate anaphylaxis or angioedema and require emergency care. Severe localized reactions have occurred and have sometimes led to dose interruption or discontinuation. Families should not assume that every reaction is harmless because it followed an injection, nor should they automatically treat it with an over-the-counter medicine without checking for interactions and obtaining the prescriber’s instructions.
How to Monitor and Give At-Home Leqembi Safely
Before the first home dose, the patient or caregiver should receive hands-on training and demonstrate that they can use the autoinjector correctly. Cognitive impairment can make an apparently simple routine unreliable: a person may forget whether the dose was given, use the wrong pen strength, or inject twice. A written dosing log, calendar reminder, and caregiver check can reduce these risks, but the clinical team must periodically reassess whether home administration remains safe. Store the autoinjectors in their original packaging in a refrigerator at 36°F to 46°F and protect them from light. Before injection, leave the prescribed pen or pens at room temperature for 20 minutes without using an external heat source.
Do not shake them, and do not use a pen that has been dropped, damaged, expired, cloudy, discolored, or visibly contaminated with particles. Once kept at room temperature, the product may remain in its original package at no more than 77°F for up to 14 days and should not be returned to the refrigerator. The abdomen and front of the thighs are approved self-injection areas; a trained caregiver or healthcare provider may also use the back of the upper arm. Avoid the two-inch area around the navel and skin containing bruises, scars, tattoos, moles, tenderness, hardness, redness, or injury. Rotate sites and stay at least one inch from the previous injection. Compared with clinic infusions, home injections reduce travel and chair time but shift storage, dose tracking, skin assessment, and sharps disposal responsibilities to the household.
Blood Thinners, APOE4, and Other Advanced Risk Issues
People with two copies of the APOE ε4 variant have a higher incidence of ARIA, including symptomatic and serious ARIA, than people with one copy or no copies. The FDA label says APOE ε4 testing should be performed before treatment to inform this risk, with counseling about what the genetic result may mean. Testing is not merely a yes-or-no eligibility screen: a higher-risk result may affect the discussion about benefits, MRI vigilance, and the household’s tolerance for uncertainty. Pretreatment microhemorrhages, superficial siderosis, and other MRI findings associated with cerebral amyloid angiopathy can also indicate greater bleeding risk.
The pivotal trial excluded people with more than four microhemorrhages and certain other concerning brain findings, limiting how confidently its safety results can be applied to patients with heavier pre-existing vascular damage. Every clinician involved in the patient’s care should know about Leqembi, particularly before prescribing anticoagulants, antiplatelet drugs, or thrombolytic treatment. Aspirin, prescription blood thinners, and even medications obtained from another clinic belong on the same reviewed medication list. Patients should not stop a necessary blood thinner on their own, but treatment with Leqembi requires particular caution when anticoagulation or other intracerebral-hemorrhage risk factors are present.
Keeping an At-Home Side-Effect Record
A useful record includes the injection date and time, pen strength, injection site, skin findings, temperature, headache severity, balance changes, and any call to the care team. Photographing a skin reaction beside a ruler can show whether redness is expanding.
A note such as “two-inch warm patch appeared four hours after the right-thigh injection and was larger the next morning” gives the clinician more usable information than “the shot caused a rash.” The record should also distinguish baseline Alzheimer’s symptoms from abrupt changes. If a person usually needs reminders but suddenly cannot form words, recognize a familiar room, or walk without veering, the caregiver should treat that as a new neurological event rather than documenting it for the next routine appointment.
Missed Doses and When the Next Injection Should Wait
If a weekly subcutaneous dose is missed, the FDA label permits administering it as soon as possible up to six days after the missed dose, followed by the next dose on the regularly scheduled day. Patients and caregivers should follow the prescribed plan rather than doubling a dose, substituting a maintenance pen for starting-dose pens, or changing the schedule themselves.
A scheduled dose should not become the priority when new neurological or serious allergic symptoms are present. The patient needs clinical guidance first, and suspected ARIA may require an MRI before treatment proceeds. Starting therapy uses two 250-milligram autoinjectors once weekly, whereas the approved weekly maintenance dose after 18 months uses one 360-milligram autoinjector.
Frequently Asked Questions
Can ARIA be detected without symptoms?
Yes. Most ARIA is asymptomatic and found through scheduled MRI monitoring, which is why a patient should not skip scans simply because they feel well.
Is every headache after Leqembi an emergency?
No, but a new, severe, persistent, or worsening headache—especially with confusion, weakness, vision changes, nausea, seizure, or difficulty walking—requires prompt medical evaluation.
Can a person with Alzheimer’s inject Leqembi without a caregiver?
Some patients may be able to self-inject after training, but cognitive or physical changes can make dose tracking and correct technique unreliable. The prescriber should periodically reassess the patient’s ability to administer it safely.
Are injection reactions the same as infusion reactions?
No. Injection reactions occur with subcutaneous Leqembi and are usually localized to the skin, although fever, chills, headache, or fatigue can occur. Infusion reactions are associated with intravenous administration and may include flu-like symptoms, breathing difficulty, heart-rate changes, or blood-pressure changes.
What should emergency clinicians be told?
Tell them the patient receives lecanemab and may be at risk for ARIA or intracerebral hemorrhage. ARIA can resemble an ischemic stroke, which matters when clinicians are considering thrombolytic medication.
